Insider transactions

EDGAR

CARIS LIFE SCIENCES, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
2 transactions, 99,050 shares
Sum of shares × price per share: 1,491,506.45
Open-market sales (code S)
7 transactions, 1,066,962 shares
Sum of shares × price per share: 28,859,273.9324

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–49 of 49

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-22 Filed 2026-09-23Denton John Russel Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,50031.8168
238,626

Derived: shares × price per share. Exact value 238626.0000.

174,855Direct (D) No
F1, F2
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F2 Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4.
Open filing 0002071923-26-000007 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-17Brille Brian J Director · Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)400,0002.44
976,000

Derived: shares × price per share. Exact value 976000.00.

630,303Direct (D) No— Open filing 0002071959-26-000008 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-17Brille Brian J Director · Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)400,00030.3302
12,132,080

Derived: shares × price per share. Exact value 12132080.0000.

230,303Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002071959-26-000008 Read from the filing’s XML Dispute this row
2026-09-17 Filed 2026-09-17Brille Brian J Director · Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (400,000) — exercise price 2.44
Disposed (D)400,0000—1,600,000Direct (D) No
F4
  • F4 The stock option is fully vested and exercisable.
Open filing 0002071959-26-000008 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-04Spetzler David Baxley Officer: President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)250,0002.44
610,000

Derived: shares × price per share. Exact value 610000.00.

1,302,083Direct (D) No— Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-04Spetzler David Baxley Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)119,21224.7552
2,951,116.9024

Derived: shares × price per share. Exact value 2951116.9024.

1,182,871Direct (D) No
F1, F4
  • F1 The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-04Spetzler David Baxley Officer: President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (250,000) — exercise price 2.44
Disposed (D)250,0000—0Direct (D) No
F5, F6
  • F5 Exercise of stock options before their expiration date.
  • F6 The stock option is fully vested and exercisable.
Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-04Spetzler David Baxley Officer: President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,000,0002.44
2,440,000

Derived: shares × price per share. Exact value 2440000.00.

1,530,083Direct (D) No— Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-04Spetzler David Baxley Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)393,10024.7604
9,733,313.24

Derived: shares × price per share. Exact value 9733313.2400.

1,136,983Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-04Spetzler David Baxley Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)84,90025.3201
2,149,676.49

Derived: shares × price per share. Exact value 2149676.4900.

1,052,083Direct (D) No
F1, F3
  • F1 The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-09-03 Filed 2026-09-04Spetzler David Baxley Officer: President
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (1,000,000) — exercise price 2.44
Disposed (D)1,000,0000—250,000Direct (D) No
F5, F6
  • F5 Exercise of stock options before their expiration date.
  • F6 The stock option is fully vested and exercisable.
Open filing 0002071953-26-000007 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14Gilliam Joseph E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—29,321Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001705850-26-000025 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14JOHANSEN LAURA I Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—343,897Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001189395-26-000002 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14Vacirca Jeff L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—62,863Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001724161-26-000008 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14PHILLIPS T DANNY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—133,060Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001239690-26-000005 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14Minor Lloyd Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—31,813Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002038687-26-000007 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14CASTLEMAN PETER M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—29,321Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001239594-26-000008 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14HALBERT JON Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—131,813Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001189394-26-000008 Read from the filing’s XML Dispute this row
2026-08-14 Filed 2026-08-14Fredrickson David Paul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)13,1920—31,813Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002071948-26-000005 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Knowles Jonathan Kenneth Charles Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,60015.62
24,992

Derived: shares × price per share. Exact value 24992.00.

308,979Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
Open filing 0001662103-26-000002 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02POSTE GEORGE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,60015.62
24,992

Derived: shares × price per share. Exact value 24992.00.

17,729Direct (D) No
F1, F2
  • F1 Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
  • F2 Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.
Open filing 0001180770-26-000003 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-07-13HALBERT JON Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)68,00014.56
990,080

Derived: shares × price per share. Exact value 990080.00.

704,598Indirect (I) By LAH Investments, Ltd.No
F2, F3, F4
  • F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F3 Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.
  • F4 The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
Open filing 0001189394-26-000005 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18Brille Brian J Director · Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)13,98715.25
213,301.75

Derived: shares × price per share. Exact value 213301.75.

230,303Direct (D) No
F1
  • F1 Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Open filing 0002071959-26-000006 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18Power Luke Thomas Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)9,77115.25
149,007.75

Derived: shares × price per share. Exact value 149007.75.

153,771Direct (D) No
F1
  • F1 Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Open filing 0002072013-26-000004 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18Spetzler David Baxley Officer: President
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)13,85615.25
211,304

Derived: shares × price per share. Exact value 211304.00.

530,083Direct (D) No
F1
  • F1 Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Open filing 0002071953-26-000004 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18HALBERT DAVID D Director · Officer: See Remarks · 10% owner
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)40,71215.25
620,858

Derived: shares × price per share. Exact value 620858.00.

2,574,533Direct (D) No
F1
  • F1 Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Open filing 0001034380-26-000004 Read from the filing’s XML Dispute this row
2026-05-15 Filed 2026-05-18Denton John Russel Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)6,04715.25
92,216.75

Derived: shares × price per share. Exact value 92216.75.

181,515Direct (D) No
F1
  • F1 Shares withheld for the payment of taxes on the vesting and settlement of RSUs.
Open filing 0002071923-26-000005 Read from the filing’s XML Dispute this row
2026-05-11 Filed 2026-05-12Vacirca Jeff L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)31,05016.149
501,426.45

Derived: shares × price per share. Exact value 501426.450.

49,671Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote
Open filing 0001724161-26-000005 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10HALBERT DAVID D Director · Officer: See Remarks · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)320,1120—2,615,245Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0001034380-26-000002 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Denton John Russel Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)63,9710—187,562Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002071923-26-000002 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Power Luke Thomas Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)63,9710—163,542Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002072013-26-000002 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Spetzler David Baxley Officer: President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)83,1620—543,939Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002071953-26-000002 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Brille Brian J Director · Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)83,1620—244,290Direct (D) No
F1
  • F1 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Open filing 0002071959-26-000004 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-03-02Minor Lloyd Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,49220.06
49,989.52

Derived: shares × price per share. Exact value 49989.52.

18,621Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0002038687-26-000004 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27HALBERT JON Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,49220.06
49,989.52

Derived: shares × price per share. Exact value 49989.52.

118,621Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0001189394-26-000002 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27CASTLEMAN PETER M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)5,50920.06
110,510.54

Derived: shares × price per share. Exact value 110510.54.

24,138Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0001239594-26-000005 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27Fredrickson David Paul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,49220.06
49,989.52

Derived: shares × price per share. Exact value 49989.52.

18,621Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0002071948-26-000002 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27Vacirca Jeff L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,49220.06
49,989.52

Derived: shares × price per share. Exact value 49989.52.

18,621Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0001724161-26-000002 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27PHILLIPS T DANNY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,73920.06
75,004.34

Derived: shares × price per share. Exact value 75004.34.

119,868Direct (D) No
F1
  • F1 Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.
Open filing 0001239690-26-000002 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13CASTLEMAN PETER M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)2,50018.60
46,500

Derived: shares × price per share. Exact value 46500.00.

18,629Direct (D) No— Open filing 0001239594-26-000003 Read from the filing’s XML Dispute this row
2026-01-09 Filed 2026-01-13CASTLEMAN PETER M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (2,500) — exercise price 18.60
Disposed (D)2,5000—0Direct (D) No
F2
  • F2 The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.
Open filing 0001239594-26-000003 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)24,7502.44
60,390

Derived: shares × price per share. Exact value 60390.00.

124,321Direct (D) Yes
F1
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)37,5002.44
91,500

Derived: shares × price per share. Exact value 91500.00.

161,821Direct (D) Yes
F1
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)60,85026.5644
1,616,443.74

Derived: shares × price per share. Exact value 1616443.7400.

100,971Direct (D) Yes
F1, F2
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,40027.1554
38,017.56

Derived: shares × price per share. Exact value 38017.5600.

99,571Direct (D) Yes
F1, F3
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (24,750) — exercise price 2.44
Disposed (D)24,7500—0Direct (D) Yes
F1, F4
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
  • F4 The stock option is fully vested and exercisable.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Power Luke Thomas Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option — underlying Common Stock (37,500) — exercise price 2.44
Disposed (D)37,5000—0Direct (D) Yes
F1, F4
  • F1 The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
  • F4 The stock option is fully vested and exercisable.
Open filing 0002072013-25-000006 Read from the filing’s XML Dispute this row
2025-12-11 Filed 2025-12-12Brille Brian J Director · Officer: See Remarks
G

Bona fide gift

Common Stock
Disposed (D)6500—161,128Direct (D) No— Open filing 0002071959-25-000009 Read from the filing’s XML Dispute this row
2025-12-10 Filed 2025-12-12Brille Brian J Director · Officer: See Remarks
G

Bona fide gift

Common Stock
Disposed (D)6500—161,778Direct (D) No— Open filing 0002071959-25-000009 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 347

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager38,330,630 SH1,174,067,187 dollarsHigher by 7,406,752 Prior quarter: 30,923,878Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager8,210,498 SH251,487,553 dollarsHigher by 8,151,395 Prior quarter: 59,103Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager7,864,791 SH240,898,549 dollarsHigher by 2,327,993 Prior quarter: 5,536,798Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager7,218,295 SH221,096,376 dollarsHigher by 7,013,477 Prior quarter: 204,818Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 5,733,874 SH175,628,561 dollarsHigher by 1,453,636 Prior quarter: 4,280,238Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager4,814,272 SH147,462 dollarsHigher by 3,608,882 Prior quarter: 1,205,390Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 4,729,952 SH144,878,430 dollarsLower by 114,479 Prior quarter: 4,844,431Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Capital World Investors Partly reported under another manager4,389,442 SH134,448,608 dollarsHigher by 3,176,170 Prior quarter: 1,213,272Open filing 0001422849-26-000169 Filed 2026-11-12 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager3,511,789 SH107,566,097 dollarsHigher by 1,141,521 Prior quarter: 2,370,268Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager3,438,241 SH108,666,801 dollarsLower by 3,120,273 Prior quarter: 6,558,514Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Sixth Street Partners Management Company, L.P. Partly reported under another manager3,032,770 SH92,893,745 dollarsLower by 4,294,271 Prior quarter: 7,327,041Open filing 0001193125-26-459444 Filed 2026-11-13 Dispute this row
LOS ANGELES CAPITAL MANAGEMENT LLC 2,963,805 SH90,781,346 dollarsLower by 994,726 Prior quarter: 3,958,531Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row
BRAIDWELL LP 2,746,688 SH84,131,053 dollarsLower by 5,509,344 Prior quarter: 8,256,032Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager2,469,931 SH75,653,987 dollarsHigher by 1,046,560 Prior quarter: 1,423,371Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
MORGAN STANLEY Partly reported under another manager2,411,539 SH73,865,439 dollarsHigher by 476,008 Prior quarter: 1,935,531Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager2,391,343 SH73,271,358 dollarsHigher by 1,346,686 Prior quarter: 1,044,657Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Amundi Partly reported under another manager2,344,238 SH71,804,010 dollarsHigher by 1,125,874 Prior quarter: 1,218,364Open filing 0001172661-26-004884 Filed 2026-11-06 Dispute this row
ORBIMED ADVISORS LLC 2,192,911 SH67,168,864 dollarsLower by 613,900 Prior quarter: 2,806,811Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
MAK CAPITAL ONE LLC 2,152,433 SH65,929,023 dollarsHigher by 215,204 Prior quarter: 1,937,229Open filing 0001019056-26-000170 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager2,138,955 SH65,516,192 dollarsHigher by 921,407 Prior quarter: 1,217,548Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
J. H. Whitney Equity Partners VI, LLC 1,750,615 SH53,621,337 dollarsLower by 9,506,000 Prior quarter: 11,256,615Open filing 0000905148-26-004761 Filed 2026-11-12 Dispute this row
FIL Ltd Partly reported under another manager1,583,262 SH48,495,315 dollarsHigher by 34,344 Prior quarter: 1,548,918Open filing 0000318989-26-000202 Filed 2026-11-10 Dispute this row
Clearbridge Investments, LLC 1,567,070 SH47,999,354 dollarsLower by 28,807 Prior quarter: 1,595,877Open filing 0001348883-26-000026 Filed 2026-11-12 Dispute this row
MILLENNIUM MANAGEMENT LLC 1,565,225 SH47,942,842 dollarsLower by 637,422 Prior quarter: 2,202,647Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
Walleye Capital LLC 1,452,377 SH44,486,308 dollarsHigher by 1,027,970 Prior quarter: 424,407Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager1,279,032 SH39,176,750 dollarsHigher by 1,235,379 Prior quarter: 43,653Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
CANADA PENSION PLAN INVESTMENT BOARD 1,243,514 SH38,088,834 dollarsLower by 131,438 Prior quarter: 1,374,952Open filing 0001104659-26-128255 Filed 2026-11-16 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager1,202,131 SH36,821,273 dollarsHigher by 916,533 Prior quarter: 285,598Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
Nuveen, LLC Partly reported under another manager1,102,981 SH33,784,308 dollarsHigher by 498,565 Prior quarter: 604,416Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
PANAGORA ASSET MANAGEMENT INC 1,061,668 SH32,518,891 dollarsHigher by 1,038,367 Prior quarter: 23,301Open filing 0000883677-26-000011 Filed 2026-11-12 Dispute this row
Champlain Investment Partners, LLC 1,053,960 SH32,282,795 dollarsHigher by 5,098 Prior quarter: 1,048,862Open filing 0001315478-26-000027 Filed 2026-11-12 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager1,031,536 SH31,595,948 dollarsHigher by 375,892 Prior quarter: 655,644Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager968,306 SH29,659,213 dollarsLower by 232,284 Prior quarter: 1,200,590Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 920,685 SH28,200,582 dollarsHigher by 878,185 Prior quarter: 42,500Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 820,060 SH25,118,438 dollarsHigher by 687,581 Prior quarter: 132,479Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager808,666 SH24,769,439 dollarsLower by 143,276 Prior quarter: 951,942Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ Partly reported under another manager792,352 SH24,269,742 dollarsHigher by 765,038 Prior quarter: 27,314Open filing 0000912938-26-001073 Filed 2026-11-12 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager773,132 SH23,681,037 dollarsHigher by 10,473 Prior quarter: 762,659Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
WORLDQUANT MILLENNIUM ADVISORS LLC Partly reported under another manager761,420 SH23,322,295 dollarsHigher by 557,268 Prior quarter: 204,152Open filing 0001745981-26-000008 Filed 2026-11-16 Dispute this row
Woodline Partners LP 723,163 SH22,150,483 dollarsUnchanged Prior quarter: 723,163Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
ZEVENBERGEN CAPITAL INVESTMENTS LLC Partly reported under another manager719,597 SH22,041,257 dollarsLower by 82,486 Prior quarter: 802,083Open filing 0001276918-26-000011 Filed 2026-10-08 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager656,500 SH20,108,595 dollarsHigher by 88,500 Prior quarter: 568,000Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager653,413 SH20,014,040 dollarsHigher by 355,558 Prior quarter: 297,855Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager635,228 SH19,457,034 dollarsHigher by 376,441 Prior quarter: 258,787Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Jump Financial, LLC Partly reported under another manager632,119 SH19,361,805 dollarsHigher by 593,626 Prior quarter: 38,493Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
TWO SIGMA INVESTMENTS, LP 558,872 SH17,118,249 dollarsHigher by 522,972 Prior quarter: 35,900Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Quantinno Capital Management LP 521,669 SH15,978,721 dollarsHigher by 79,997 Prior quarter: 441,672Open filing 0001759654-26-000011 Filed 2026-11-13 Dispute this row
ING GROEP NV 496,100 SH15,195,543 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-042914 Filed 2026-11-10 Dispute this row
Trexquant Investment LP Partly reported under another manager483,870 SH14,820,938 dollarsLower by 244,074 Prior quarter: 727,944Open filing 0001633445-26-000008 Filed 2026-11-16 Dispute this row
NEUBERGER BERMAN GROUP LLC 452,695 SH13,866,048 dollarsLower by 3,138,268 Prior quarter: 3,590,963Open filing 0001465109-26-000128 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • COATUE MANAGEMENT LLC 9,819,992 SH
  • T. Rowe Price Investment Management, Inc. 5,079,141 SH
  • Duquesne Family Office LLC 1,894,450 SH
  • HRT FINANCIAL LP 1,418,392 SH
  • Squarepoint Ops LLC 380,927 SH
  • TD Asset Management Inc 379,388 SH
  • MENLO ADVISORS LLC 300,518 SH
  • Qube Research Technologies Ltd 226,878 SH
  • MARSHALL WACE, LLP 222,717 SH
  • Maxi Investments CY Ltd 210,670 SH
  • SG Americas Securities, LLC 152,236 SH
  • CastleKnight Management LP 132,236 SH
  • NATIXIS 124,716 SH
  • Smartleaf Asset Management LLC 94,051 SH
  • Pathstone Holdings, LLC 82,782 SH
  • MOORE CAPITAL MANAGEMENT, LP 63,895 SH
  • Jupiter Research Capital (Asia) Ltd 52,754 SH
  • Caption Management, LLC 50,000 SH
  • Y-Intercept (Hong Kong) Ltd 46,068 SH
  • EntryPoint Capital, LLC 33,719 SH
  • PURA VIDA INVESTMENTS, LLC 25,500 SH
  • Aquatic Capital Management LLC 22,068 SH
  • INTERCAPITAL, LLC 20,000 SH
  • Summit Trail Advisors, LLC 19,248 SH
  • Tidal Investments LLC 18,422 SH
  • Tidal Investments LLC 18,400 SH
  • DARK FOREST CAPITAL MANAGEMENT LP 17,710 SH
  • WINTON GROUP Ltd 14,800 SH
  • Quantum Portfolio Management LLC 14,343 SH
  • Scientech Research LLC 13,670 SH
  • Hudson Bay Capital Management LP 12,870 SH
  • Aigen Investment Management, LP 12,568 SH
  • GROUP ONE TRADING LLC 12,397 SH
  • Magnetar Financial LLC 11,504 SH
  • Caprock Group, LLC 11,206 SH
  • Bridgefront Capital, LLC 11,028 SH
  • DRW Securities, LLC 10,031 SH
  • Index Technologies Group LLC 7,390 SH
  • Freestone Grove Partners LP 3,655 SH
  • MCF Advisors LLC 2,000 SH
  • NATIONAL BANK OF CANADA /FI/ 96 SH
  • Cornerstone Planning Group LLC 78 SH
  • Parallel Advisors, LLC 34 SH
  • MassMutual Private Wealth Trust, FSB 25 SH
  • Caption Management, LLC 19 SH
  • Kilter Group LLC 16 SH
  • MV CAPITAL MANAGEMENT, INC. 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
FMR LLC COMMON STOCK13.437,795,316.6609/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002724 Dispute this row
Abigail P. Johnson COMMON STOCK13.437,795,316.6609/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002724 Dispute this row
J H Whitney VI L P Common Stock, par value $0.001 per share4.011,256,61506/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003576 Dispute this row
J. H. Whitney Equity Partners VI, LLC Common Stock, par value $0.001 per share4.011,256,61506/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003576 Dispute this row
VIGANO PAUL R Common Stock, par value $0.001 per share4.011,256,61506/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003576 Dispute this row
WILLIAMS ROBERT M JR Common Stock, par value $0.001 per share4.011,256,61506/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003576 Dispute this row
TSSP Sub-Fund HoldCo, LLC Common Stock, par value $0.001 per share2.46,732,770.0006/30/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-340353 Dispute this row
Alan Waxman Common Stock, par value $0.001 per share2.67,327,041.0006/30/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-340353 Dispute this row
J H Whitney VI L P Common Stock, par value $0.001 per share6.518,256,61503/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002222 Dispute this row
J. H. Whitney Equity Partners VI, LLC Common Stock, par value $0.001 per share6.518,256,61503/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002222 Dispute this row
VIGANO PAUL R Common Stock, par value $0.001 per share6.518,256,61503/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002222 Dispute this row
WILLIAMS ROBERT M JR Common Stock, par value $0.001 per share6.518,256,61503/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002222 Dispute this row
TSSP Sub-Fund HoldCo, LLC Common Stock, par value $0.001 per share4.813,666,128.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-219598 Dispute this row
Alan Waxman Common Stock, par value $0.001 per share5.114,385,399.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-219598 Dispute this row
FMR LLC COMMON STOCK10.830,631,585.0003/31/2026 Filed 2026-04-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-000715 Dispute this row
Abigail P. Johnson COMMON STOCK10.830,631,585.0003/31/2026 Filed 2026-04-07SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-000715 Dispute this row
TSSP Sub-Fund HoldCo, LLC Common Stock, par value $0.001 per share6.518,416,128.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051538 Dispute this row
Alan Waxman Common Stock, par value $0.001 per share6.919,385,399.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-051538 Dispute this row
FMR LLC COMMON STOCK5.014,143,768.0012/31/2025 Filed 2026-02-05SCHEDULE 13GOpen filing 0000315066-26-000404 Dispute this row
Abigail P. Johnson COMMON STOCK5.014,143,768.0012/31/2025 Filed 2026-02-05SCHEDULE 13GOpen filing 0000315066-26-000404 Dispute this row
J H Whitney VI LP Common Stock, par value $0.001 per share7.320,256,61506/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001140361-25-031213 Dispute this row
J. H. Whitney Equity Partners VI, LLC Common Stock, par value $0.001 per share7.320,256,61506/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001140361-25-031213 Dispute this row
VIGANO PAUL R Common Stock, par value $0.001 per share7.320,256,61506/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001140361-25-031213 Dispute this row
WILLIAMS ROBERT M JR Common Stock, par value $0.001 per share7.320,256,61506/30/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001140361-25-031213 Dispute this row
David D. Halbert Common Stock44.1124,906,296.0006/30/2025 Filed 2025-08-13SCHEDULE 13GOpen filing 0001104659-25-077539 Dispute this row
Caris Halbert, L.P. Common Stock36.0101,261,532.0006/30/2025 Filed 2025-08-13SCHEDULE 13GOpen filing 0001104659-25-077539 Dispute this row
TSSP Sub-Fund HoldCo, LLC Common Stock, par value $0.001 per share ("Common Stock").8.323,166,128.0006/30/2025 Filed 2025-07-28SCHEDULE 13GOpen filing 0000950170-25-099203 Dispute this row
Alan Waxman Common Stock, par value $0.001 per share ("Common Stock").8.824,385,399.0006/30/2025 Filed 2025-07-28SCHEDULE 13GOpen filing 0000950170-25-099203 Dispute this row
Riverview Group LLC Common Stock, par value $0.001 per share1.12,985,503.0006/17/2025 Filed 2025-06-24SCHEDULE 13GOpen filing 0001104659-25-062132 Dispute this row
Millennium Management LLC Common Stock, par value $0.001 per share1.33,583,100.0006/17/2025 Filed 2025-06-24SCHEDULE 13GOpen filing 0001104659-25-062132 Dispute this row
Millennium Group Management LLC Common Stock, par value $0.001 per share1.33,583,100.0006/17/2025 Filed 2025-06-24SCHEDULE 13GOpen filing 0001104659-25-062132 Dispute this row
Israel A. Englander Common Stock, par value $0.001 per share1.33,583,100.0006/17/2025 Filed 2025-06-24SCHEDULE 13GOpen filing 0001104659-25-062132 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,598,888 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020224,461
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to CARIS LIFE SCIENCES, INC.